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Natural killer cell deficiency (NKD) is a primary immunodeficiency where the main defect
lies in CD56+CD3− natural killer (NK) cells which mediate cytotoxicity against tumors.
Most cases are observed in children and adolescents with recurrent viral infections and
cancer. GATA2 and MCM4 mutations are found in NKD patients with cancer. However,
the question remains unclear whether NKD increases the risk of cancer. Mutations in
the second zinc finger of GATA2 cause both NKD and haematopoietic malignancies.
MCM4 splice site mutations are found in NKD patients and they increase susceptibility to
DNA instability during replication. IRF8, RTEL1, and FCGR3A mutations are associated
with NKD but their associations with cancer are unknown. Based on the studies, it is
hypothesized that genetic mutations alone are sufficient to cause cancer. However, a
number of NKD patients developed oncogenic viral infections which progressed into
cancer. Here, we review the evidence of genetic mutations responsible for both NKD
and cancer to identify whether NKD contributes to development of cancer. The findings
provide insights into the role of NK cells in the prevention of cancer and the significance
of assessing NK cell functions in susceptible individuals.
Keywords: NKD, NK cells, oncogenic viral infections, CD56bright NK cells, MDS-AML
INTRODUCTION
NK cells mediate cytotoxicity against tumor and viral infected cells. NK cells have activating and
inhibitory receptors (1) which allow NK cells to selectively target pathogenic cells while preventing
autoimmunity against autologous cell (2). The inhibitory receptors are activated by MHC-I while
activating receptors are activated by activating ligands on pathogenic cells (2). NK cells play
important role in cancer immunity as they mediate cytotoxicity against tumor cells that evade
CD8+ T cells by up-regulating activating ligands and failing to express MHC-I (3). In addition, NK
cells interact with dendritic cells and T cells to mediate cytotoxicity against tumor cells. Dendritic
cells secrete cytokines which activate NK cells, resulting in NK cell secretion of perforin and
expression of TNF ligands such as FASL and TRAIL that are responsible for tumor cell apoptosis
(4). Conversely, NK cells present antigen debris that activate dendritic cells and they secrete IFNγ
that activate T cells, resulting in cytotoxicity against tumor cells (4).
Moon and Powis NKD and Cancer
The role of NK cells in cancer immunity has been
demonstrated from NK cell deficient mice and humans.
NK1.1+CD3− cell deficient transgenic mice showed poor tumor
cell removal and increased metastasis compared to wild type
in vivo (5). NK cells suppress spontaneous and MCA carcinogen
induced tumor formation in mice (3). Furthermore, cancer
patients with low peripheral or intratumoral NK cell activity
have poorer survival rates (6) and low NK cell cytotoxicity
facilitates the progression of precancerous disease into cancer (7)
as well as metastases (8). An 11-year cohort study of Japanese
residents illustrated that participants in the lowest tertile of
natural cytotoxicity were more likely to develop cancer (9).
In humans, NKD has been defined as a primary defect in
the number or function of CD56+CD3− NK cell in peripheral
blood which is caused by genetic abnormalities that persist over
time (10). NKD can be subdivided into classical natural killer cell
deficiency (CNKD) and functional natural killer cell deficiency
(FNKD) (10). CNKD is defect in both number and function of
NK cells in peripheral blood whereas FNKD results in only a
functional defect (10). The mutations in GATA2, MCM4, IRF8,
and RTEL1 are associated with CNKD and substitutions in
FCGR3A with FNKD (11).
The observational studies of NK cell deficient mice and
humans have illuminated that NK cells contribute to tumor
surveillance. The cancers have been observed in NKD patients
with GATA2 andMCM4mutations although not in patients with
IRF8, RTEL1, and FCGR3Amutations (11). Despite these aspects,
it is unclear whether NKD is a risk factor of cancer due to a
difficulty in isolating NK cell defects as NK cells share receptors
and cytokines with other immune cells. This poses the question
of whether genetically defined NKDs weaken cancer immunity
which cannot be overcome by other immune cells. If NKD
increases susceptibility to at least some cancers, it would be worth
assessing the number and cytotoxicity of NK cells to prevent such
cancers. This review explores whether NKD increases the risk of
cancer, based on existing literature.
GATA2 MUTATIONS ARE ASSOCIATED
WITH AML-MDS
GATA2 regulates the proliferation and survival of multi-potent
haematopoietic stem cells (12). GATA2 mutations selectively
affect NK cells, B cells, dendritic cells, and monocytes (12).
GATA2 mutations have been observed in CNKD patients
with haematopoietic malignancies, especially myelodysplastic
syndrome, and acute myeloid leukemia (MDS-AML) (12). DNA
sequencing of four MDS-AML families identified missense and
frameshift mutations at Thr354 and Thr355 in the second
zinc finger of GATA2 (13). Both mutations resulted in the
production of abnormal GATA2 proteins that lacked an affinity
to the consensus DNA and PU.1 transcription factor (13).
When the mutant GATA2 was transfected to promyelocytes,
they proliferated substantially and failed to undergo apoptosis
when treated with all-trans retinoic acid (ATRA) in vitro
unlike those transfected with wild-type GATA2 (14). The same
GATA2 mutations have been identified in Emberger syndrome
(14), MonoMac syndrome (15) and dendritic cell, monocyte, B
and NK lymphoid (DCML) deficiency (16), which accompany
both MDS-AML and deficiency in NK cells. The observations
reinforced that GATA2 controls haematopoiesis and therefore its
disruption results in cancer in affected cell lineages.
Mace et al. found that patients with GATA2 mutations had
CD56bright subset loss and consequently increased proportion
of CD56dim subset, regardless of total NK cell count (12). In
addition, there was significant downregulation of NKG2D and
reduced cytotoxicity per NK cell in these patients, indicating that
GATA2 may be crucial for producing functional NK cells as well
as maintaining CD56bright NK cells (12). The downregulation of
NKG2D compromises NK cell cytotoxicity inMDS and facilitates
progression to AML (17). Furthermore, leukemic cells shed
activating ligands to evade NK cell cytotoxicity, indicating role
of NK cells in leukemia (18). Therefore, NKD caused by GATA2
mutations is associated with increased risk of MDS-AML.
MCM4 MUTATION INCREASES THE RISK
OF CANCER
The oncogenic mechanism of MCM4 mutation was revealed by
the genetic mapping of mice erythrocytes, which showed that
mutant MCM4Chaos3 allele causes T to A substitution in the
downstream of the MCM4 zinc finger, resulting in amino acid
change in F345I (19).Whenmouse embryonic fibroblasts (MEFs)
were transfected with DNAs containing MCM4Chaos3 allele, they
were more susceptible to breakage when their DNAs were
treated with aphidicolin. This suggested that MCM4 mutations
produce non-functional MCM4 protein that has increased DNA
instability upon replication stress.
Similarly, the genetic mapping of MCM4 mutation of the
four Irish children with CNKD identified premature stop codon,
resulting in shortened MCM4 proteins that lacked N-terminal
domain containing F345I as observed in mice (20, 21). The
affected children had reduced number of CD56dim NK cell as
well as reduced total number of NK cells and they had immature
CD56bright NK cells (12). One of them had lymphoproliferative
disorder which progressed to EBV induced lymphoma (20).
When the fibroblasts of the patients were stimulated with
cytokines produced by CD56bright NK cells, there were defects
in their DNA replication (12). Therefore, high chromosomal
breakage may have contributed to development of EBV induced
lymphoma in this patient. The mutant alleles may not always
lead to cancer even if they increase DNA instability as the
complex interplay of genes and environmental factors determines
occurrence of cancer (3). This explains why three out of four Irish
CNKD children (20) did not develop cancer despite having the
same MCM4 mutations (22). Therefore, MCM4 mutations are
associated with both NKD and increased susceptibility to DNA
instability upon stress.
NKD INCREASES SUSCEPTIBILITY TO
VIRUS RELATED CANCER
Most solid tumors observed in NKD patients are associated
with oncogenic viral infections, especially Epstein Barr Virus
(EBV), and Human Papilloma Virus (HPV). However, there are
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no reported cases of hepatitis B and C, HTLV-1, and KSHV
induced cancers in NKD patients so far (23). The role of NK
cells in virus driven malignancies is unclear although NK cells
may indirectly suppress tumor growth as tumor cells have
mechanisms of evading NK cell cytotoxicity (16). As with MDS-
AML, NK activating receptors are downregulated in HPV-16
driven cervical cancer patients, indicating dysfunction of NK cells
in these patients (24). The compromised NK cell cytotoxicity
against oncogenic viral infection results in viral gene transfection
(25) and inflammatory responses (26), both of which predispose
to oncogenic changes, as observed in an Irish NKD patient with
EBV-related lymphoma (20, 22) (Figure 1).
The effect of NKD on non-viral induced cancer remains
unknown. A 56-year-old patient with FNKD developed multiple
cutaneous squamous cell carcinoma (cSCC) unresponsive to
chemoradiotherapy (32). However, her HPV serology was
negative, hence cSCC was not induced by HPV (32). Similarly,
NKD has been observed in a few patients with breast cancer and
solid tumors but the mechanism of oncogenesis is unknown (33).
Therefore, while NKD increases the risk of certain virus induced
cancer, its effect on non-viral induced cancer not associated with
GATA2 and MCM4 mutations is unknown.
The viral driven malignancies have been observed in patients
with normal NK cells as well as in NKD patients (9, 33). While
incidence of cancer in both groups cannot be compared due
to small number of studies conducted across different periods
of time among patients of various demographics, Spinner et al.
(33) found that patients with normal NK cell counts were less
likely to have major complications including severe infection and
cancer than NKD patients. Also, such patients were likely to
have fewer number of complications than those with low NK
cell counts. Similarly, Imati et al. (9) reported higher relative
risk of cancer incidence in patients with low natural cytotoxicity
(1.0) in comparison to those with higher natural cytotoxicity
(0.6). While the results were not specific to NK cells as natural
cytotoxicity is exerted by several innate cells, the study illustrated
the significance of natural cytotoxicity in increased incidence
of cancer.
NKD AND HODGKIN’S LYMPHOMA
The first case of viral-induced cancer in an NKD patient
was observed in a 12-year-old girl with isolated CNKD who
developed EBV related smooth muscle tumors (SMTs) in the
bilateral adrenal glands (27). The patient had longstanding
latent EBV infection, during which EBV transfects its gene into
host DNA, facilitating development of cancer (27) (Figure 1).
FIGURE 1 | NKD and viral induced cancer. NKD results in reduced number of NK cells (11) and downregulation of activating receptors against oncogenic viruses (24).
This increases the susceptibility to EBV and HPV infections which subsequently progress into cancer (27–31). In addition, NKD compromises cytotoxicity against
viruses during the infection allowing viral genes to be transfected into infected cells which transform into cancerous cells (23, 25). The arrows indicate the increased
risk of developing conditions on the box that it is pointing to.
FIGURE 2 | Summary of association between NKD and cancer. Arrows indicate association between the box it is emerging from and the box it is pointing to. GATA2,
MCM4, IRF8, RTEL1, and FCGR3A are the genes responsible for NKD. GATA2 increases the risk of MDS-AML MCM4 is associated with increased NDA instability.
NKD is associated with increased susceptibility to MDS-AML and some oncogenic viral infections. NKD has been observed in other solid tumors and breast cancer
although association on between them is unknown.
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Therefore, the case suggests that NKD may have increased
the risk of SMTs during latent EBV infection. Similar cases
have been reported in a 6-year-old Taiwanese girl (28) and
one of the three siblings (29, 30) with isolated NKDs who
developed Hodgkin’s lymphoma in the latent phase of EBV
infection which may have been facilitated by NKD. While EBV
downregulates NKG2D expression on NK cells to evade NK
mediated cytotoxicity (23), NKD was present before primary
EBV infection and persisted after complete recovery from the
lymphoma in these patients (29, 30). Therefore, NKD was not
transiently caused by EBV but it rather increased the risk of
lymphoma (29, 30). In addition, NK cells have cytotoxicity
against EBV infected B cells and they prevent transformation of
EBV infected B cells into cancer in the acute EBV infection (23).
Therefore, NKD increases the risk of EBV induced lymphoma
by facilitating progression into cancer in acute and latent EBV
infection. Furthermore, considering its antiviral immunity, NK
cells may increase the risk of lymphoma by increasing the
risk of developing EBV infection which subsequently progresses
into lymphoma.
NKD AND CARCINOMA IN SITU
OF CERVIX
Finally, HPV driven cervical cancer is one of the most
common virus drivenmalignancies in NKD patients withGATA2
mutations. In a retrospective study of 57 patients with GATA2
mutations, more than one third of patients had HPV driven
malignancies (33). Similar to GATA2 deficient patients with
MDS-AML, patients with HPV driven malignancies had low
number of CD56bright NK cells (11). Spinner et al. found
that almost all GATA2 deficient patients with one or more
complications of severe infections, MDS-AML, and pulmonary
alveolar proteinosis had significantly decreased NK cell counts
(33). This was in contrast to patients without such complications,
whose median NK cell count fell within the normal range (33).
This implied the crucial role of NK cells in preventing GATA2
associated fatal diseases including HPV driven malignancies.
Similarly, a 23-year-old girl diagnosed with recurrent carcinoma
in situ of cervix (31) had peripheral blood mononuclear cells
(PBMCs) which responded poorly against K562 on several
occasions compared to the controls’ PBMCs. The poor natural
cytotoxicity was attributed to NK cell numbers, as the proportion
of NK cells defined as CD3−CD16+ and CD3−NKH1+ cells was
very low unlike CD3+ T cells. The NK cell selective markers
were used to conclude that cytotoxicity of NKT and T cells was
not sufficient to defense against HPV in the absence of NK cells.
The observations imply the crucial role of NK cells on immunity
against HPV driven malignancies (11).
CONCLUSION
In conclusion, most NKD cases with cancer have been observed
in children and adolescents who have compromised immunity.
The relatively small cohort size of NKD patients inevitably
limits somewhat the generalization of the findings. Nevertheless,
GATA2 related autosomal dominant syndromes provide strong
evidence that substitution and frameshift GATA2 mutations at
N-terminal to and within the second zinc finger cause both
CNKD and MDS-AML. Both mice and human studies suggest
that frameshift mutation at MCM4 splice site results in the
production of non-functional MCM4 protein which increases
susceptibility to DNA instability upon replication stress. IRF8,
RTEL1, and FCGR3A mutations have been observed in NKD
patients but their association with cancer is unknown. NKD
may compromise anti-EBV immunity during acute and latent
infections, facilitating the development of EBV induced cancer.
However, the precise mechanisms of NK cell mediated EBV
cytotoxicity need to be elucidated to consolidate such findings.
The HPV induced cancer observed in CNKD patients imply the
potential role of NK cells on HPV induced cancer. Therefore,
NKD may increase the risk of cancers associated with certain
viruses and mutations while future studies on mechanisms of
cancer in NKD patients would highlight the role of NK cells in
cancer immunity (Figure 2).
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